Baxter International (BAX)
(Delayed Data from NYSE)
$38.49 USD
-0.27 (-0.70%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $38.50 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
A Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.49 USD
-0.27 (-0.70%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $38.50 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
A Value F Growth D Momentum D VGM
Zacks News
3 Medical Device Stocks with Solid Potential to Buy Now
by Zacks Equity Research
The Medical Device industry has been riding high on optimism of late, courtesy of the Senate's latest decision to lacerate the Affordable Care Act (ACA) by the end of July.
Baxter International (BAX) Up 6.7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Baxter International (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights: Baxter International, Lantheus Holdings, OraSure Technologies, MAM Software Group and Teradyne
by Zacks Equity Research
Zacks.com featured highlights: Baxter International, Lantheus Holdings, OraSure Technologies, MAM Software Group and Teradyne
Quest Diagnostics Poised on Solid Q1 Results Despite Woes
by Zacks Equity Research
On May 22, we issued an updated research report on Quest Diagnostics, Inc. (DGX), a major commercial laboratory services provider.
Medtronic (MDT) RESOLUTE ONYX Meets Primary Study Endpoint
by Zacks Equity Research
Medtronic plc (MDT) recently announced favorable outcome on its Resolute Onyx Drug-Eluting Stent.
5 Top Efficient Stocks to Add to Your Portfolio
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns
Edwards Lifesciences SAPIEN 3 Heart Valve Data Positive
by Zacks Equity Research
Edwards Lifesciences Corporation (EW) recently unveiled positive one-year data on its SAPIEN 3 transcatheter heart valve.
TransEnterix (TRXC) Reports Wider-than-Expected Loss in Q1
by Zacks Equity Research
TransEnterix, Inc. (TRXC) reported a loss of 13 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 12 cents.
Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up
by Zacks Equity Research
Masimo Corp. (MASI) reported earnings of 57 cents per share in the first quarter of 2017, outperforming the Zacks Consensus Estimate of 54 cents and improving from the year-ago quarterly earnings of 53 cents.
Medtronic (MDT) Wins FDA Approval for CRT-P SureScan Suite
by Zacks Equity Research
Medtronic plc (MDT) recently won FDA approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers that improve therapy delivery for patients with heart failure.
STERIS (STE) Grapples with Headwinds: Should You Dump?
by Zacks Equity Research
On May 10, we issued an updated research report on STERIS Plc (STE) which manufactures and markets infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services.
New Strong Buy Stocks for May 12th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
Hologic (HOLX) Tops Q2 Earnings & Sales, Raises 2017 View
by Zacks Equity Research
Hologic Inc. (HOLX) reported second-quarter fiscal 2017 adjusted earnings per share (EPS) of 50 cents, up 6.4% year over year.
Genomic Health (GHDX) Misses Q1 Earnings & Sales Estimates
by Zacks Equity Research
Genomic Health, Inc. (GHDX) reported first-quarter 2017 loss per share of 7 cents, reflecting an improvement from the year-ago quarter's loss figure of 19 cents.
Dull Q1 Earnings & Tough Industry Spell Trouble for BioScrip
by Zacks Equity Research
On May 10, we issued an updated research report on BioScrip, Inc. (BIOS ), a pure-play Infusion Service provider.
Becton (BDX) Announces $4.5B Follow-On Share Offerings
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced a follow-on offering of $4.5 billion for its shares.
STERIS (STE) Tops Q4 Earnings & Revenues, Issues '18 View
by Zacks Equity Research
STERIS Plc (STE) reported fourth-quarter fiscal 2017 adjusted earnings per share (EPS) of $1.11, up 23.3% from the year-ago quarter.
Penumbra (PEN) Q1 Loss Wider than Expected, View Intact
by Zacks Equity Research
Penumbra, Inc. (PEN), that went public in Sep 2015, reported first-quarter 2017 loss of 10 cents per share, comparing unfavorably with earnings of 7 cents year over year.
PetMed (PETS) Beats Earnings, Revenue Estimates in Q4
by Zacks Equity Research
PetMed Express, Inc. (PETS) announced earnings per share of 37 cents for the fourth quarter of fiscal 2017, up 37% from the year-ago quarter's 27 cents.
Henry Schein (HSIC) Tops Q1 Earnings, Reaffirms '17 View
by Zacks Equity Research
Henry Schein, Inc. (HSIC) reported adjusted earnings per share (EPS) of $1.76 in the first quarter of 2017, up 24.8% year over year.
Haemonetics (HAE) Tops Q4 Earnings, Sales, Issues 2018 View
by Zacks Equity Research
Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2017, up 5.4% year over year.
Phibro (PAHC) Posts In Line Earnings in Q3, Revises View
by Zacks Equity Research
Phibro Animal Health Corporation (PAHC) reported adjusted earnings per share (EPS) of 37 cents in the third quarter of fiscal 2017, down 7.5% year over year.
Align Technology Invisalign Sales Strong, Currency Woes Stay
by Zacks Equity Research
On May 5, we issued an updated research report on Align Technology (ALGN), which manufactures a system of clear aligner therapy.
Qiagen Banks on Molecular Diagnostic amid Currency Woes
by Zacks Equity Research
On May 4, we issued an updated research report on leading molecular diagnostic company, Qiagen N.V. (QGEN).
CVS Down on Weak Earnings, Pharmacy Services Remains Strong
by Zacks Equity Research
On May 5, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS).